Pathos AI is fir­ing on all cylin­ders. The tech­nol­o­gy and drug de­vel­op­ment com­pa­ny told End­points News that it signed a ma­jor an­ti­body-drug con­ju­gate (ADC) deal with a Chi­nese biotech and teamed up with its CEO's for­mer em­ploy­er to de­vel­op an­oth­er can­cer as­set...